TG Ther­a­peu­tics signs $645M deal to kick-start in­ter­na­tion­al launch of MS an­ti­body 

TG Ther­a­peu­tics is look­ing to ex­pand ac­cess to its CD20 an­ti­body Briumvi out­side North Amer­i­ca and has an­nounced a part­ner­ship with the Eu­ro­pean phar­ma com­pa­ny …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER